Powerful targeted next-generation sequencing for cancer research
Cancer is a complex, heterogeneous disease of the genome, affecting both germline and somatic cells. Most cancers result from an accumulation of multiple genetic alterations that lead to dysfunction of cancer-associated genes. Next-generation sequencing (NGS) enables you to get more results, more quickly, in a single test.
With Oncomine Assays and Ion Torrent Sequencing you can perform sequencing of hundreds of cancer genes concurrently using very low input amounts of FFPE DNA and RNA. With integrated workflows from sample through annotation, and clinical NGS experts to help you every step of the way, we can get you up and running quickly.
Get more from your tumor sample with Oncomine NGS Assays
Traditional genetic testing methods involve single-gene tests performed in succession to determine the presence or absence of variants of interest. Because of sample size requirements for running each test and the number of tests required to narrow in on the right answer, sequential testing can often lead to inconclusive results. Additionally, sequential testing can be laborious and expensive, requiring many weeks of work before finding the right answer.
With next generation sequencing (NGS) you can analyze your sample for hundreds of variants of interest using a single sample in a single experiment. You can detect hotspots, SNVs, indels, CNVs and gene fusions in a single run. And with Ion AmpliSeq™ technology, you only need a few FFPE slides or 10 ng of sample DNA and RNA to see results.
Ion AmpliSeq™ technology—less tumor sample, more answers
Oncomine Assays leverage proven Ion AmpliSeq technology for tumor analysis. Ideal for cancer research, Ion AmpliSeq™ technology delivers a simple and fast workflow for targeted NGS of specific human genes or genomic regions. Based on ultrahigh-multiplex PCR, Ion AmpliSeq™ technology requires as little as 10 ng of input DNA or RNA to simultaneously target up to hundreds of genes, making sequencing of FFPE samples or fine-needle aspirates routine on the Ion PGM™ System. This technology enables you to work with samples that may contain partially degraded or limited genomic material, run more samples than you have in the past, and lower acceptance thresholds for tumor samples to generate more reportable results.
Faster results speed you to your next steps
Using Oncomine Assays, along with the Ion PGM™ System and Ion Reporter™ Software, streamline your workflow so you can get results faster. This simple, optimized system takes you from sample to variants in a day. Designed for flexibility, the chip-based Ion PGM™ System enables you to run from one to hundreds of samples without sacrificing affordability. This means you can run your samples on your time, eliminating the time spent waiting to run a full batch with larger, less flexible NGS systems.
For Research Use Only. Not for use in diagnostic procedures.